what this is, and what it is not
About this CJC-1295 digest
An independent editorial reading of the published literature — and a plain statement of what the word 'pharmacy' in the name does and does not mean.
What this project is
Pharmacy CJC-1295 is an independent editorial project that publishes summaries of the peer-reviewed research literature on CJC-1295. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.
The approach is simple: read the published record straight, lead with what was measured, attribute every number to its study, and mark plainly where the evidence stops. CJC-1295's literature is unusually narrative — a multi-day half-life, a preserved-pulsatility result, an albumin-bioconjugate design story, a discontinued Phase 2 program, a perennial DAC-versus-no-DAC confusion. We read it as the after-hours feature it deserves to be, not as a dashboard of selling points.
What 'pharmacy' means here
The word "pharmacy" in this site's name is editorial framing, not a claim about services. It signals the register we read the literature in — a who-studies-it, what-the-pharmacology-shows reading room — not a dispensary, a counter, or a prescribing service.
To be unambiguous: nothing is dispensed, prescribed, compounded, or sold here. There is no pharmacist on staff, no clinical team, and no inventory. CJC-1295 is an unapproved research chemical with no approved human indication anywhere [9], and this site exists to document its research record, not to facilitate access to it.
How we handle the evidence
We separate strength of evidence carefully. The human pharmacokinetics — the multi-day GH and IGF-1 elevation, the 5.8-8.1 day half-life — come from controlled Phase 1 studies and are reported as such [2]. The synergy rationale for the ipamorelin pairing rests on replicated mechanism studies [7]. Claims that lack controlled human support — body-composition outcomes, optimal dosing, long-term safety — are named as gaps, not dressed up as findings [9].
Where registries disagree on a molecular detail (the exact formula and mass of CJC-1295 are listed differently across CAS and PubChem), we flag the disagreement rather than pick a side silently. The point is a reader who leaves knowing what is established, what is plausible, and what is simply unknown.